这份卒中后机械取栓治疗共识声明的原始版本于2014年11月16—18日在斯德哥尔摩召开的欧洲卒中组织（European Stroke Organisation, ESO）-卡罗林斯卡卒中更新会议期间得到批准。根据会议安排，在2015年利用新的临床试验数据对该声明进...这份卒中后机械取栓治疗共识声明的原始版本于2014年11月16—18日在斯德哥尔摩召开的欧洲卒中组织（European Stroke Organisation, ESO）-卡罗林斯卡卒中更新会议期间得到批准。根据会议安排，在2015年利用新的临床试验数据对该声明进行了更新。2015年2月，在瑞士伯尔尼召开的ESO冬季培训会期间组织了面对面会议对共识声明进行修订，然后通过电子邮件交换意见，最终版本得到各学会的认可。推荐意见与原始版本一致，证据等级更新到2015年2月20日为止，在2015年5月15日获得确认。ESO-卡罗林斯卡卒中更新会议的目的在于总结卒中治疗研究的最新进展并探讨如何将这些最新研究结果应用于临床实践。共识会议选择了一些议题进行讨论，与会者草拟一份共识声明并进行讨论。该声明接受了ESO指南委员会的指导。这份共识声明包括对急性卒中后机械取栓治疗的推荐意见，得到欧洲卒中组织ESO、欧洲神经微创治疗学会（European Society of Minimally Invasive Neurological Therapy, ESMINT）、欧洲神经放射学学会（European Society of Neuroradiology, ESNR）和欧洲神经病学学会（European Academy of Neurology, EAN）的支持。展开更多
Background We investigated outcomes in patients with intracerebral haemorrhage(ICH)according to prior anticoagulation treatment with Vitamin K antagonists(VKAs),direct oral anticoagulants(DOACs)or no anticoagulation.M...Background We investigated outcomes in patients with intracerebral haemorrhage(ICH)according to prior anticoagulation treatment with Vitamin K antagonists(VKAs),direct oral anticoagulants(DOACs)or no anticoagulation.Methods This is an individual patient data study combining two prospective national stroke registries from Switzerland and Norway(2013–2019).We included all consecutive patients with ICH from both registries.The main outcomes were favourable functional outcome(modified Rankin Scale 0–2)and mortality at 3 months.Results Among 11349 patients with ICH(mean age 73.6 years;47.6%women),1491(13.1%)were taking VKAs and 1205(10.6%)DOACs(95.2%factor Xa inhibitors).The median percentage of patients on prior anticoagulation was 23.7(IQR 22.6–25.1)with VKAs decreasing(from 18.3%to 7.6%)and DOACs increasing(from 3.0%to 18.0%)over time.Prior VKA therapy(n=209(22.3%);adjusted ORs(aOR),0.64;95%CI,0.49 to 0.84)and prior DOAC therapy(n=184(25.7%);aOR,0.64;95%CI,0.47 to 0.87)were independently associated with lower odds of favourable outcome compared with patients without anticoagulation(n=2037(38.8%)).Prior VKA therapy(n=720(49.4%);aOR,1.71;95%CI,1.41 to 2.08)and prior DOAC therapy(n=460(39.7%);aOR,1.28;95%CI,1.02 to 1.60)were independently associated with higher odds of mortality compared with patients without anticoagulation(n=2512(30.2%)).Conclusions The spectrum of anticoagulation-associated ICH changed over time.Compared with patients without prior anticoagulation,prior VKA treatment and prior DOAC treatment were independently associated with lower odds of favourable outcome and higher odds of mortality at 3.展开更多
文摘这份卒中后机械取栓治疗共识声明的原始版本于2014年11月16—18日在斯德哥尔摩召开的欧洲卒中组织（European Stroke Organisation, ESO）-卡罗林斯卡卒中更新会议期间得到批准。根据会议安排，在2015年利用新的临床试验数据对该声明进行了更新。2015年2月，在瑞士伯尔尼召开的ESO冬季培训会期间组织了面对面会议对共识声明进行修订，然后通过电子邮件交换意见，最终版本得到各学会的认可。推荐意见与原始版本一致，证据等级更新到2015年2月20日为止，在2015年5月15日获得确认。ESO-卡罗林斯卡卒中更新会议的目的在于总结卒中治疗研究的最新进展并探讨如何将这些最新研究结果应用于临床实践。共识会议选择了一些议题进行讨论，与会者草拟一份共识声明并进行讨论。该声明接受了ESO指南委员会的指导。这份共识声明包括对急性卒中后机械取栓治疗的推荐意见，得到欧洲卒中组织ESO、欧洲神经微创治疗学会（European Society of Minimally Invasive Neurological Therapy, ESMINT）、欧洲神经放射学学会（European Society of Neuroradiology, ESNR）和欧洲神经病学学会（European Academy of Neurology, EAN）的支持。
文摘Background We investigated outcomes in patients with intracerebral haemorrhage(ICH)according to prior anticoagulation treatment with Vitamin K antagonists(VKAs),direct oral anticoagulants(DOACs)or no anticoagulation.Methods This is an individual patient data study combining two prospective national stroke registries from Switzerland and Norway(2013–2019).We included all consecutive patients with ICH from both registries.The main outcomes were favourable functional outcome(modified Rankin Scale 0–2)and mortality at 3 months.Results Among 11349 patients with ICH(mean age 73.6 years;47.6%women),1491(13.1%)were taking VKAs and 1205(10.6%)DOACs(95.2%factor Xa inhibitors).The median percentage of patients on prior anticoagulation was 23.7(IQR 22.6–25.1)with VKAs decreasing(from 18.3%to 7.6%)and DOACs increasing(from 3.0%to 18.0%)over time.Prior VKA therapy(n=209(22.3%);adjusted ORs(aOR),0.64;95%CI,0.49 to 0.84)and prior DOAC therapy(n=184(25.7%);aOR,0.64;95%CI,0.47 to 0.87)were independently associated with lower odds of favourable outcome compared with patients without anticoagulation(n=2037(38.8%)).Prior VKA therapy(n=720(49.4%);aOR,1.71;95%CI,1.41 to 2.08)and prior DOAC therapy(n=460(39.7%);aOR,1.28;95%CI,1.02 to 1.60)were independently associated with higher odds of mortality compared with patients without anticoagulation(n=2512(30.2%)).Conclusions The spectrum of anticoagulation-associated ICH changed over time.Compared with patients without prior anticoagulation,prior VKA treatment and prior DOAC treatment were independently associated with lower odds of favourable outcome and higher odds of mortality at 3.
